Literature DB >> 26319445

Medical Treatment of Primary Canine Glaucoma.

Anthony F Alario1, Travis D Strong2, Stefano Pizzirani3.   

Abstract

Glaucoma is a painful and often blinding group of ocular diseases for which there is no cure. Although the definition of glaucoma is rapidly evolving, elevated intraocular pressure (IOP) remains the most consistent risk factor of glaucoma in the canine patient. Therapy should be aimed at neuroprotection. The mainstay of therapy focuses on reducing IOP and maintaining a visual and comfortable eye. This article discusses the most current ocular hypotensive agents, focusing on their basic pharmacology, efficacy at lowering IOP, and recommended use in the treatment of idiopathic canine glaucoma.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Carbonic anhydrase inhibitors; Delivery systems; Glaucoma; Medical therapy; Novel therapies; Prostaglandin analogues

Mesh:

Substances:

Year:  2015        PMID: 26319445     DOI: 10.1016/j.cvsm.2015.06.004

Source DB:  PubMed          Journal:  Vet Clin North Am Small Anim Pract        ISSN: 0195-5616            Impact factor:   2.093


  1 in total

1.  Effects of topical administration of tafluprost and combination of tafluprost and timolol or tafluprost and betaxolol on Schirmer tear test, intraocular pressure, and pupil size in clinically healthy dogs.

Authors:  Armin Shokoohimand; Farnoosh Arfaee; Ahmad Asghari; Ehsan Khaksar
Journal:  Int Ophthalmol       Date:  2020-06-05       Impact factor: 2.031

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.